Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in First Complete Remission after Donor Stem Cell Transplant

This phase II trial studies how well ruxolitinib phosphate works in treating older patients with acute myeloid leukemia in first complete remission after donor stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Hematologic, Leukemia
Phase II
Adults
Mol. targeted/Immunotherapy/Biologics
Ruxolitinib
Byrne, Michael
National
Vanderbilt University
06-27-2018
Treatment
VICCBMT1778
NCT03286530

Eligibility

Not Available
Not Available
NO
Inclusion Criteria:

Participants must have pathologically confirmed acute myeloid leukemia (AML) in first complete remission (CR1) as defined by: * Bone marrow biopsy with = 1000/uL (achieved post-induction at some point) * Please note that full platelet recovery is not necessary, and thus, patients achieving pathological complete remission (CRp) are eligible

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: